Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of “Hold” from Brokerages

Rezolute, Inc. (NASDAQ:RZLT) has been assigned an average rating of “Hold” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $8.75.

A number of brokerages recently weighed in on RZLT. Wedbush upgraded shares of Rezolute from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $2.00 to $5.00 in a report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Rezolute in a report on Tuesday, April 21st. Maxim Group lifted their price objective on shares of Rezolute from $4.00 to $10.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wall Street Zen upgraded shares of Rezolute from a “strong sell” rating to a “sell” rating in a report on Saturday.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RZLT. RA Capital Management L.P. purchased a new position in Rezolute in the fourth quarter worth approximately $21,665,000. Opaleye Management Inc. lifted its stake in Rezolute by 595.9% in the fourth quarter. Opaleye Management Inc. now owns 6,287,156 shares of the company’s stock worth $14,838,000 after acquiring an additional 5,383,714 shares during the last quarter. Jennison Associates LLC purchased a new position in Rezolute in the first quarter worth approximately $10,489,000. Siren L.L.C. purchased a new position in Rezolute in the first quarter worth approximately $10,151,000. Finally, Balyasny Asset Management L.P. lifted its stake in Rezolute by 147.3% in the fourth quarter. Balyasny Asset Management L.P. now owns 4,506,861 shares of the company’s stock worth $10,636,000 after acquiring an additional 2,684,133 shares during the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.

More Rezolute News

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: HC Wainwright raised its Q1 2027 EPS estimate, indicating a somewhat better outlook for that quarter. Rezolute analyst estimate update
• Positive Sentiment: The firm also increased its Q2 2027 EPS estimate, another modest improvement in the near-term earnings view. Rezolute analyst estimate update
• Positive Sentiment: HC Wainwright lifted its FY2027 EPS forecast, implying better expected profitability over the medium term. Rezolute analyst estimate update
• Neutral Sentiment: The analyst also updated FY2028 and FY2029/FY2030 estimates, reflecting a broader refresh of the company’s longer-term model. Rezolute analyst estimate update
• Negative Sentiment: HC Wainwright cut its Q4 2026 EPS estimate, signaling weaker expected results in the next reported period. Rezolute analyst estimate update
• Negative Sentiment: The firm lowered its Q3 2027 and Q4 2027 EPS estimates, which may have contributed to the stock moving lower. Rezolute analyst estimate update
• Negative Sentiment: HC Wainwright also reduced its FY2026, FY2028, FY2029, and FY2030 EPS forecasts, pointing to slower anticipated earnings improvement over time. Rezolute analyst estimate update

Rezolute Stock Performance

Shares of RZLT stock opened at $3.34 on Monday. The stock has a market capitalization of $321.61 million, a P/E ratio of -4.07 and a beta of 0.66. The company has a 50 day moving average price of $3.14 and a 200 day moving average price of $4.50. Rezolute has a fifty-two week low of $1.07 and a fifty-two week high of $11.46.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. On average, research analysts forecast that Rezolute will post -0.72 EPS for the current fiscal year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.